3-Prime launched to focus on serving the R&D market

Prime Synthesis Inc. announced a new operating division, called 3-Prime LLC, intented to provide support to customers for oligonucleotide production in the research and development market.

Chris Anderson
Register for free to listen to this article
Listen with Speechify
ASTON, Pa.—Prime Synthesis Inc. a develop­er of DNA synthesis support products aimed primarily at the clinical and drug manu­facturing markets, recently announced the formation of a new operating division called 3-Prime LLC, with the intent of providing the same solid support used by these cus­tomers for oligonucleotide production for the research and development market.
According to Marc Rothstein, president of 3-Prime, the intent of creating a separate division focused on the research market was to be able to provide the customized service needed to maximize oligo yields and produc­tion at the half dozen or so companies provid­ing these materials to the research markets.
"We have seen that there have been a lot of interesting developments and collabora­tions occurring in the research market," he says. "As more and more companies look to perform genomic research, there is an increasing need for oligos to support them and we are in a position to provide value to the companies producing the oligos."
In order to ensure that its support prod­ucts are of the highest standard, 3-Prime has turned to one of these manufacturers, Integrated DNA Technologies (IDT), to test and validate its products.
According to Trey Martin, COO of IDT: "Researchers working with 3-Prime not only [will] receive effec­tive product for their work, but they will also benefit from IDT's analytical expertise and our expe­rience in high-throughput oligo production."
While 3-Prime is providing mate­rials that aid high-volume oligo producers, Rothstein says there is very little fear that any of 3-Prime's potential customers would take that capability in-house.
"While nothing we do is pat­ent-protected, we have learned our own trade secrets over the years and have become very efficient at what we do," Rothstein says. "With oligo prices around 50 cents per base, these companies would rather focus their time and effort on further automating their pro­duction and increasing efficiency of their operation than spending a lot of time developing things they can easily get from us."

Chris Anderson

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

September 2023 issue front cover

Latest Issue  

• Volume 19 • Issue 8 • September 2023

September 2023

September 2023 Issue